{"url_path":"/sec/bbio/8-k/2026-06-26/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-026506-index.html","accession_number":"0001140361-26-026506","cik":"0001743881","ticker":"BBIO","issuer_name":"BridgeBio Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-026506-index.html","primary_entity_key":"0001743881","primary_entity_name":"BridgeBio Pharma, Inc."},"word_count":311,"has_tables":true,"body_markdown":"false000174388100017438812026-06-222026-06-22\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 8-K\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): June 26, 2026 (June 22, 2026)\n\nBridgeBio Pharma, Inc.\n\n(Exact name of registrant as specified in its charter)\n\nDelaware\n\n001-38959\n\n84-1850815\n\n(State or other jurisdiction of incorporation)\n\n(Commission File Number)\n\n(IRS Employer Identification No.)\n\n3160 Porter Dr.,\nSuite 250\n\nPalo Alto, CA\n\n94304\n\n(Address of principal executive offices)\n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (650) 391-9740\n\nNot Applicable\n\n(Former name or former address, if changed since last report)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the\nfollowing provisions:\n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nCommon Stock, par value $0.001 per share\n\nBBIO\n\nThe Nasdaq Global Select Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec. 230.405 of this\nchapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec. 240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new\nor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}